Clinical Trials on Chronic Hepatitis C

Total 35685 results

Minneapolis Veterans Affairs Medical Center
US Department of Veterans Affairs; Kadmon Corporation, LLC; InterMune; San Diego... and other collaborators

Completed

Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial

Chronic Hepatitis C
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (POSITRON)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico, Australia
Vertex Pharmaceuticals Incorporated
ViroChem Pharma

Completed

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Hepatitis C

Canada, United States, Argentina, Puerto Rico
Biolex Therapeutics, Inc.

Completed

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C (PLUS)

Hepatitis C

United States
University Health Network, Toronto
Schering-Plough

Terminated

EXtended Therapy in Hepatitis C Genotype 3 Infected Patients (EXACT-R(3))

Chronic Hepatitis C

Canada
Bristol-Myers Squibb

Completed

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Chronic Hepatitis C

United States
University Hospital, Basel, Switzerland

Completed

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Hepatitis C

Switzerland
Tehran Hepatitis Center
Kermanshah University of Medical Sciences

Completed

Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C

Hepatitis C

Iran, Islamic Republic of
Antipodean Pharmaceuticals, Inc.

Completed

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Chronic Hepatitis C

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Hepatitis | Hepatitis C

United States
University of Nebraska

Terminated

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

Chronic Hepatitis C | Relapse | Genotype 1

United States
Gilead Sciences

Terminated

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Hepatitis C Virus Infection

France, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
National Institute of Diabetes and Digestive and...
National Cancer Institute (NCI); National Institute of Allergy and Infectious... and other collaborators

Completed

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment (HALT-C)

Fibrosis, Liver | Cirrhosis, Liver | Hepatic Cirrhosis | Chronic Hepatitis c

United States
Peking University First Hospital

Recruiting

The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China (BDTAF)

Chronic Hepatitis B | Chronic Hepatitis C

China
MTmedical Institute of Health
The University of Texas Health Science Center at San Antonio; BioMonde Preparations...

Unknown

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

Chronic Hepatitis B | Chronic Hepatitis C

United States
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

HCV Infection

United States, Germany, Poland, Sweden
National Institute of Diabetes and Digestive and...

Completed

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

Chronic Hepatitis C

United States
University of Bern
Roche Pharma AG; University of Lausanne; University of Basel; Cantonal Hospital... and other collaborators

Completed

High Dose Ribavirin in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

Switzerland
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments

Chronic Hepatitis C

Taiwan
Palo Alto Veterans Institute for Research
Hoffmann-La Roche

Completed

Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C

Obesity | Chronic Hepatitis C

United States
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (LIFE-C)

Chronic Hepatitis C
AbbVie
IST GmbH, Germany

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary (VERITAS)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

HIV Infections | Hepatitis C | Chronic Hepatitis C
Rennes University Hospital
Novartis

Terminated

Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation

Chronic Hepatitis C | Evidence of Liver Transplantation

France
Assiut University

Completed

Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy

Chronic Hepatitis c

Egypt
Bristol-Myers Squibb

Completed

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction (PK)

Chronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus Infection

United States
Atea Pharmaceuticals, Inc.

Withdrawn

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Hepatitis C Virus Infection

United States, Puerto Rico
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium, Mauritius, Moldova, Republic of
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Hepatitis C Virus Infection

Russian Federation, Sweden
AbbVie

Completed

Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis (EASY)

Hepatitis C Virus (HCV)

Russian Federation
Saint Michael's Medical Center

Completed

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

HIV Infection | Hepatitis C Infection

United States
Muhammad Radzi Abu Hassan

Recruiting

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Hepatitis C

Malaysia
University of Florida
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie

Completed

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Chronic Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) (C-WORTHy)

Hepatitis C
Changi General Hospital
National University Hospital, Singapore

Completed

Epidemiology of Chronic Hepatitis C and Disease Modelling (EPIC)

Hepatitis C

Singapore
Merck Sharp & Dohme LLC

Completed

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Chronic Hepatitis C
Assiut University

Unknown

Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs

Hepatitis C
Janssen R&D Ireland

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients (RESTORE)

Hepatitis C

France, Belgium
Microbio Co Ltd

Unknown

A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients

Chronic Hepatitis C

Taiwan
Association HGE CHU Bordeaux Sud
University Hospital, Bordeaux

Completed

Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir (GENUPI)

Chronic Hepatitis C

France
Memorial Sloan Kettering Cancer Center

Completed

SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study

Hepatitis C

United States
Bristol-Myers Squibb

Completed

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Hepatitis C

United States, Australia, Canada, France, Puerto Rico
Bristol-Myers Squibb
Pharmasset

Completed

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Chronic Hepatitis C

United States, Puerto Rico
Biocad

Completed

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

Hepatitis | Hepatitis C

Russian Federation
Janssen R&D Ireland
Gilead Sciences

Completed

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (COSMOS)

Hepatitis C

United States, Puerto Rico

3

Subscribe